Quarterly results Archives - Page 10 of 13

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

Business, Chapter 11 Bankruptcy, Clinical Studies, Dermatologicals, Psoriasis, Quarterly results, Shares, T-Cells, Tropomyosin receptor kinase A (TrkA) inhibitors

Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.

September 18, 2019/by BioSpace

Novo Nordisk’s new diabetes, obesity drugs lift sales outlook

Analysts, Business, Financials, Forecasts, Glucagon-Like Peptide-1 (GLP-1) Analogs, Injectables, Insulin, Obesity, Quarterly results, Reuters Polls, Trading, Type 2 Diabetes

Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.

August 9, 2019/by Reuters Health

Israel’s Teva Pharm profit falls less than expected, CFO to leave

Analysts, Business, Departures, Financials, Forecasts, Opioids, People on the Move, Quarterly results, Settlements, Shares

Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter 2019 profit and said the chief financial officer was leaving the company.

August 7, 2019/by Reuters Health

Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.

July 29, 2019/by BioSpace

AbbVie Raises 2019 Profit Target

Despite concerns about potential competition from recently approved and available European biosimilars to Humira, AbbVie was able to stave off some of the losses expected during Q2 2019.

July 26, 2019/by BioSpace

Roche lifts full-year outlook after H1 sales rise 18 percent

Acquisitions, Blockbusters, Business, Cancer, Gene Therapy, Immunotherapies, Multiple Sclerosis, Quarterly results

Roche lifted the company’s full-year sales outlook after revenue in first-half 2019 rose 18 percent, helped by newer drugs including the MS medicine Ocrevus and the cancer immunotherapy Tecentriq.

July 25, 2019/by Reuters Health

Multiple sclerosis drug helps Biogen beat Wall St. profit expectations

Analysts, Blockbusters, Business, Multiple Sclerosis, Quarterly results, Shares, Spinal Muscular Atrophy (SMA), Therapeutics, Wall Street Estimates

Biogen Inc. reported better-than-expected second quarter 2019 profit and raised the company’s full-year earnings forecast, driven by higher sales of the top-selling multiple sclerosis drug Tecfidera and lower taxes.

July 23, 2019/by Reuters Health

States Pause Lawsuits Against Insys During Bankruptcy Proceedings

Bankruptcy, Business, Department Of Justice, Epidemics, FDA, Lawsuits, New Drug Applications, Opioid Overdoses, Opioids, Quarterly results, Settlements

Less than a month after filing for bankruptcy, Insys Therapeutics gained a reprieve from some lawsuits as well as a path forward for regulatory approval of an opioid overdose treatment.

July 3, 2019/by BioSpace

Insys Therapeutics Files for Bankruptcy

Bankruptcy, Business, Cannabinoids, Chapter 11 Bankruptcy, Cost Cutting, Fraudulent marketing schemes, Government, Kickbacks, Litigation, Opioids, Product Pipelines, Quarterly results, Shares, Strategy

Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.

June 10, 2019/by BioSpace

Gilead to separate Kite cell therapy unit

Acquisitions, Analysts, Business, CAR-T Therapy, Cell Therapy, Financials, Hepatitis C, HIV, Liver Damage, Lymphomas, Product Pipeline, Quarterly results, Shares, Wall Street

Gilead Sciences Inc. said Kite Pharma Inc., the cancer-focused cell therapy company acquired in 2017, will become a separate business unit.

May 2, 2019/by Reuters Health